Literature DB >> 15698816

Development of medicines for children in Europe: ethical implications.

Agnès Saint Raymond1, Daniel Brasseur.   

Abstract

Ethics of clinical trials in children have been a longstanding topic for debate. Children are vulnerable, unable to consent to participation in trials from a legal perspective and deserve to be protected. Ethical principles and the European legal framework define the safeguards that need to be put in place in any paediatric trial, be it performed in developed or in developing countries. It was considered that children should not be included in trials for ethical reasons. However, there is an ethical need to study medicines as data obtained in adults cannot be extrapolated to children. It is our collective responsibility to obtain sufficient information to be able to prescribe medicines safely whilst protecting children who are exposed in the trials. Future European paediatric regulations should encourage the development of medicines in high-quality ethical research and ensure availability of information to the public.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Substances:

Year:  2005        PMID: 15698816     DOI: 10.1016/j.prrv.2004.11.008

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  8 in total

Review 1.  The EU's new paediatric medicines legislation: serving children's needs?

Authors:  Govin Permanand; Elias Mossialos; Martin McKee
Journal:  Arch Dis Child       Date:  2007-09       Impact factor: 3.791

Review 2.  Children's presence in research. A review of online registers.

Authors:  C Pandolfini; M Bonati
Journal:  Eur J Clin Pharmacol       Date:  2009-07-10       Impact factor: 2.953

Review 3.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

Review 4.  Clinical trials in children.

Authors:  Pathma D Joseph; Jonathan C Craig; Patrina H Y Caldwell
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

5.  The Dutch Medicines for Children Research Network: a new resource for clinical trials.

Authors:  Elske H Weber; Ivo T F Timmermans; Martin Offringa
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

6.  Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

Authors:  Anne E M Brabers; Ellen H M Moors; Sonja van Weely; Remco L A de Vrueh
Journal:  Orphanet J Rare Dis       Date:  2011-09-05       Impact factor: 4.123

7.  Oral medicines for children in the European paediatric investigation plans.

Authors:  Diana A van Riet-Nales; Erwin G A W Römkens; Agnes Saint-Raymond; Piotr Kozarewicz; Alfred F A M Schobben; Toine C G Egberts; Carin M A Rademaker
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

8.  Are Regulatory Age Limits in Pediatric Melanoma Justified?

Authors:  Klaus Rose; Philip D Walson
Journal:  Curr Ther Res Clin Exp       Date:  2019-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.